| abstract |
The present disclosure relates to bifunctional compounds which find utility as estrogen receptor (target protein) modulators. in particular, the present disclosure is directed to bifunctional compounds containing at one end at least one of a von hippel lindau ligand, a cereblon ligand, apoptosis protein ligand inhibitors, homologous double-minute ligand 2 mouse, or a combination thereof, which binds to its ubiquitin ligase e3 and, at the other end, a moiety that binds to the target protein, so that the target protein is placed in close proximity to the ubiquitin ligase for degradation (and inhibition) of the target protein. The present disclosure discloses a wide range of pharmacological activities associated with degradation / inhibition of the target protein. Diseases or disorders resulting from aggregation or accumulation of the target protein are treated or prevented with the compounds and compositions of the present disclosure. |